Sonnet BioTherapeutics Analyst Ratings
Sonnet BioTherapeutics Analyst Ratings
While ratings are subjective and will change, the latest Sonnet BioTherapeutics (SONN) rating was a with a price target of $0.00 to $6.70. The current price Sonnet BioTherapeutics (SONN) is trading at is $0.28, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/23/2023 | 2317.9% | EF Hutton | → $6.7 | Assumes | → Buy |
| 08/16/2023 | 4230.57% | Chardan Capital | $14 → $12 | Maintains | Buy |
| 06/26/2023 | 2317.9% | EF Hutton | → $6.7 | Reiterates | Buy → Buy |
| 05/25/2023 | 2317.9% | EF Hutton | → $6.7 | Assumes | → Buy |
| 05/11/2023 | 4952.33% | Chardan Capital | $17 → $14 | Maintains | Buy |
| 04/19/2023 | 2317.9% | EF Hutton | → $6.7 | Reiterates | → Buy |
| 04/19/2023 | 6034.97% | Chardan Capital | $22 → $17 | Maintains | Buy |
| 02/15/2023 | 2317.9% | EF Hutton | → $6.7 | Reiterates | → Buy |
| 12/19/2022 | 2317.9% | EF Hutton | → $6.7 | Initiates Coverage On | → Buy |
| 09/22/2022 | 7839.37% | Chardan Capital | $2 → $22 | Maintains | Buy |
| 08/16/2022 | 621.76% | Chardan Capital | $2.5 → $2 | Maintains | Buy |
| 02/09/2022 | 621.76% | BTIG | $5 → $2 | Maintains | Buy |
| 12/20/2021 | 802.2% | Chardan Capital | $8 → $2.5 | Maintains | Buy |
| 12/16/2021 | 621.76% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
| 09/15/2021 | 1704.4% | BTIG | → $5 | Initiates Coverage On | → Buy |
| 09/04/2020 | 2787.04% | Chardan Capital | $7 → $8 | Maintains | Buy |
| 06/05/2020 | 2426.16% | Chardan Capital | → $7 | Initiates Coverage On | → Buy |
| 日期 | 利好/利空 | 分析師公司 | 目標價調整 | 評級變更 | 前一評級 / 當前評級 |
|---|---|---|---|---|---|
| 08/23/2023 | 2317.9% | EF Hutton | → $6.7 | Assumes | → 買入 |
| 08/16/2023 | 4230.57% | 查丹資本 | $14 → $12 | 維持 | 買入 |
| 06/26/2023 | 2317.9% | EF Hutton | → $6.7 | 重申 | 買入 → 買入 |
| 05/25/2023 | 2317.9% | EF Hutton | → $6.7 | Assumes | → 買入 |
| 05/11/2023 | 4952.33% | 查丹資本 | $17 → $14 | 維持 | 買入 |
| 04/19/2023 | 2317.9% | EF Hutton | → $6.7 | 重申 | → 買入 |
| 04/19/2023 | 6034.97% | 查丹資本 | $22 → $17 | 維持 | 買入 |
| 02/15/2023 | 2317.9% | EF Hutton | → $6.7 | 重申 | → 買入 |
| 12/19/2022 | 2317.9% | EF Hutton | → $6.7 | 開始覆蓋 | → 買入 |
| 09/22/2022 | 7839.37% | 查丹資本 | $2 → $22 | 維持 | 買入 |
| 08/16/2022 | 621.76% | 查丹資本 | $2.5 → $2 | 維持 | 買入 |
| 02/09/2022 | 621.76% | BTIG | $5 → $2 | 維持 | 買入 |
| 12/20/2021 | 802.2% | 查丹資本 | $8 → $2.5 | 維持 | 買入 |
| 12/16/2021 | 621.76% | HC Wainwright & Co. | → $2 | 開始覆蓋 | → 買入 |
| 09/15/2021 | 1704.4% | BTIG | → $5 | 開始覆蓋 | → 買入 |
| 09/04/2020 | 2787.04% | 查丹資本 | $7 → $8 | 維持 | 買入 |
| 06/05/2020 | 2426.16% | 查丹資本 | → $7 | 開始覆蓋 | → 買入 |
What is the target price for Sonnet BioTherapeutics (SONN)?
Sonnet BioTherapeutics（SONN）的目標價是多少？
The latest price target for Sonnet BioTherapeutics (NASDAQ: SONN) was reported by EF Hutton on August 23, 2023. The analyst firm set a price target for $6.70 expecting SONN to rise to within 12 months (a possible 2317.90% upside). 10 analyst firms have reported ratings in the last year.
Sonnet BioTherapeutics（納斯達克：SONN）的最新目標價由EF Hutton在2023年8月23日報告。分析師公司設定的目標價爲6.70美元，預計SONN在12個月內會上漲（可能的2317.90%的上漲空間）。過去一年有10家分析師公司報告了評級。
What is the most recent analyst rating for Sonnet BioTherapeutics (SONN)?
Sonnet BioTherapeutics（SONN）最近期的分析師評級是什麼？
The latest analyst rating for Sonnet BioTherapeutics (NASDAQ: SONN) was provided by EF Hutton, and Sonnet BioTherapeutics their buy rating.
Sonnet BioTherapeutics（納斯達克：SONN）最新的分析師評級由EF Hutton提供，Sonnet BioTherapeutics給出了買入評級。
When is the next analyst rating going to be posted or updated for Sonnet BioTherapeutics (SONN)?
Sonnet BioTherapeutics（SONN）下一個分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sonnet BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sonnet BioTherapeutics was filed on August 23, 2023 so you should expect the next rating to be made available sometime around August 23, 2024.
分析師在經過廣泛研究後給出股票評級，這包括查看公衆基本報表，和Sonnet BioTherapeutics的高管及客戶交談，並收聽業績發佈會電話會議。大多數分析師每三個月進行一次評估，因此每年每家公司的每個公司應該會獲得4個評級。Sonnet BioTherapeutics的最後一個評級是在2023年8月23日登記的，因此您應該期待下一個評級在2024年8月23日左右發佈。
Is the Analyst Rating Sonnet BioTherapeutics (SONN) correct?
Sonnet BioTherapeutics（SONN）的分析師評級是否正確？
While ratings are subjective and will change, the latest Sonnet BioTherapeutics (SONN) rating was a with a price target of $0.00 to $6.70. The current price Sonnet BioTherapeutics (SONN) is trading at is $0.28, which is within the analyst's predicted range.
雖然評級是主觀的並會發生變化，但最新的Sonnet BioTherapeutics（SONN）評級爲，並且目標價區間爲0.00美元到6.70美元。目前Sonnet BioTherapeutics（SONN）的交易價格爲0.28美元，處於分析師預測的區間內。
譯文內容由第三人軟體翻譯。
